The Sevoflurane, Isoflurane
and Desflurane Market is expected to reach USD 1.5 billion by 2022 in
comparison to USD 1.2 billion in 2014. These three chemicals are inhalation
agents and have been used by anesthesiologists, nurse anesthetists, and
anesthesiology assistants on a consistent basis. They are very strong and cost
less, with minimum damage to the ozone layer.
Market Drivers
One of the
primary factors, triggering expansion in the sevoflurane, isoflurane and
desflurane market includes cardiovascular and respiratory diseases affecting
the geriatric population. Rising cancer, orthopedic, spinal and
gastro-intestinal cases have also furthered the market. Cataract surgery is a
major contributor to the global market and will need a higher production of
these chemicals.
Growing accidents
and emergency cases also add income to the inhalation anesthesia market.
Universal insurance coverage as well as constant improvements in medical
infrastructure also ensure the development of the sevoflurane, isoflurane and
desflurane market. These agents are administered to patients prior surgery,
making the induction of general anesthesia much simpler.
A major factor
hindering the market is the quantity of CO2 released in the
environment, leading to global warming. Actually, only about 5
percent of the gases are consumed by patients. The rest are released into the
atmosphere and make it unhealthy. The most practical solution for this problem
is the anesthetic recycling of products used during the administration of
general anesthesia.
Browse Details of Report@
Products Overview
Sevoflurane
Sevoflurane is
one of the most commonly used volatile anesthetic agents. It is administered to
babies and children. Sevoflurane is ideal for patients with asthma or sensitive
air passages. But its side-effects include delirium and agitation. It can be
given quickly without the use of intravenous instruments.
Sevoflurane would
capture over 70% of the worldwide sevoflurane, isoflurane and desflurane market
by 2022. The agent is expected to exceed USD 1 billion by the same year. It’s
widely utilized for being low-priced and possessing therapeutic benefits.
Isoflurane
Isoflurane is a
halogen ether utilized frequently by veterinarians. It is administered
intravenously, relaxes the muscles and reduces pain. Isoflurane has also been
used for inducing sleepiness for long durations during surgery. It is expected
to register a CAGR of about 10% by 2022.
Desflurane
Desflurane is a
halogen ether used in general anesthesia. Its effectiveness is one-fifth of
isoflurane. Desflurane cannot be administered orally and requires an
electrically heated dispenser to distribute the vapor. It is mostly administered
to bariatric patients and in cases of surgeries lasting for short durations.
Regional Overview
The United States
has a large geriatric population. This has led the region of North America to
occupy the biggest share in the worldwide inhalation anesthesia market in 2014.
Surgical ambulatory and inpatient procedures are the driving factors of North
America.
Asia Pacific will
experience the fastest growth by 2022. This is owing to the rise of chronic
diseases and need for better health infrastructure in the region. Medical
tourism combined with insurance coverage will play a huge role in sustaining
the growth of the sevoflurane, isoflurane and desflurane market.
Key Players
The market is
currently dominated by AbbVie and Baxter International. However, it can
expect strong competition from manufacturers like Lunan Pharmaceutical
Group and Piramal Enterprises.
Piramal
Enterprises currently has isoflurane and sevoflurane production underway. It
will manufacture generic desflurane by 2016. AbbVie has sevoflurane and
isoflurane under production. Baxter International is the only one that
manufactures all the three products.
Anesthesia has
some unhealthy effects. The recycling companies of Deltasorb Technologies and
Anesthetic Gas Reclamation reprocess anesthesia containers and gases from
hospital vents. Rising investments by the aforementioned players would also
accelerate the sales of the sevoflurane, isoflurane and desflurane market.
Browse Related Category Market
Reports@
About Us:
Hexa Research is a market research and
consulting organization, offering industry reports, custom research and
consulting services to a host of key industries across the globe. We offer
comprehensive business intelligence in the form of industry reports which help
our clients obtain clarity about their business environment and enable them to
undertake strategic growth initiatives.
Contact Us:
Ryan Shaw
Hexa Research
Felton Office Plaza
6265 Highway 9
Felton, California 95018
United States
Phone: +1-800-489-3075
Email: sales@hexaresearch.com
Website - http://www.hexaresearch.com/
Visit Our Blog - https://hexaresearchinc.wordpress.com/
Hexa Research
Felton Office Plaza
6265 Highway 9
Felton, California 95018
United States
Phone: +1-800-489-3075
Email: sales@hexaresearch.com
Website - http://www.hexaresearch.com/
Visit Our Blog - https://hexaresearchinc.wordpress.com/
No comments:
Post a Comment